Inflammation and cancer: The macrophage connection

Medicina

Volumn 67, Issue SUPPL. 2, 2007, Pages 32-34

  Mantovani, Alberto ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Cancer; Inflammation; Macrophages

Indexed keywords

ARGINASE; CHEMOKINE; CHEMOKINE RECEPTOR; GAMMA INTERFERON; GROWTH FACTOR; INTERLEUKIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1; ONCOPROTEIN; ORNITHINE; POLYAMINE; PROTEIN RET; SCAVENGER RECEPTOR; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ANTIMICROBIAL ACTIVITY; ARTICLE; CARCINOGENESIS; CELL FUNCTION; CELL POPULATION; CELL PROLIFERATION; DRUG TARGETING; EFFECTOR CELL; GENE REARRANGEMENT; HUMAN; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MACROPHAGE ACTIVATION; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; MICROENVIRONMENT; MOLECULAR MECHANICS; PHAGOCYTE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THYROID PAPILLARY CARCINOMA; TISSUE REPAIR; TUMOR CELL DESTRUCTION;

EID: 34548499681     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211-7.
2. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45.
3. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
4. Mantovani A. Cancer: inflammation by remote control. Nature 2005; 435: 752-3.
5. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-55.
6. Mantovani A, ed. Chemokines in Neoplastic Progression. Seminars Cancer Biol. Vol. 14. 2004.
7. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-26.
8. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159-69.
9. Koehne CH, Dubois RN. COX-2 inhibition and colorectal cancer. Semin Oncol 2004; 31: 12-21.
10. Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 2003; 100: 2645-50.
11. Wyckoff J, Wang W, Lin EY, et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 2004; 64: 7022-9.
12. Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-6.
13. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-296.
14. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000; 103: 481-90.
15. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005; 7: 411-23.
16. Borsi L, Balza E, Carnemolla B, et al. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 2003; 102: 4384-92.
17. Sangaletti S, Stoppacciaro A, Guiducci C, Torrisi MR, Colombo MP. Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma. J Exp Med 2003;198: 1475-85.
18. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35.
19. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-86.
20. Borrello MG, Alberti L, Fischer A, et al. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci USA 2005; 102: 14825-30.
21. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-48.
22. Colombo MP, Mantovani A. Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. Cancer Res 2005; 65: 9113-6.